Telithromycin has demonstrated good in vitro activity against gram-negative pathogens responsible for rtis and temodar. Sep 20, 2007 all eight clinical streptococcus pneumoniae isolates were resistant to erythromycin with mics 128 micron g ml and had telithromycin mics 2 micron g ml cnnmoney ketek safety concerns persist - sep 24, 2007 ketek telithromycin ; is part of the ketolide class of antibiotics, and was approved by the fda in april of 200 the drug has been shrouded in controversy injuryboard , ketek telithromycin ; no longer approved in canada for treatment.

A classical planning problem is a 4-tuple F, I, G, A where: fluents F are a set of predicate symbols; initial state I is completely defined by predicates in F ; goal state G is partially defined by a set of predicates in F ; a set of actions A with a A are defined by pre- and post-conditions P re a ; , Add a ; , Delete a ; F . plan P is a sequence of actions that when executed from I achieves all goals g G. In partial satisfaction planning PSP ; [Smith, 2004; van den Briel et al., 2004], goals g G have utility values ug 0, representing how much each goal is worth to the user; each action a A has an associated execution cost ca 0, representing how costly it is to execute each action e.g. amount of time or resources consumed ; . Let GP G be the set of goals achieved by a plan P . The objective is to find a plan P that maximizes the difference between total achieved utility u GP ; and total cost of all actions a P i.e., plan benefit ; : ca 1 ; MAX u GP and tenex.

The visual adverse events found with telithromycin occurred after any of the doses during treatment, but most followed the first or second dose.
Hossam Al-Tatari, Nahed Abdel-Haq et al Telithromycin is active against erythromycinsusceptible Staphylococcus aureus and isolates that can export or enzymatically degrade macrolides. Telithromycin is not active against S. aureus isolates that constitutvely express erm genes. It is also inactive against MRSA isolates.61, 69 Although S. aureus isolates with inducible MLSB resistance are susceptible in vitro to telithromycin, erm resitance has been reported to switch from inducible to constitutive expression. This will limit the clinical efficacy of telithromycin in treating infections caused by S. aureus with MLSB inducible phenotype.63 Telithromycin is active against many gram-positive and gram-negative anaerobes including Peptostreptococcus spp., Clostridium spp., Bacteroides spp.70 Telithormycin has been shown to be active against intracellular and extracellular Helicobacter pylori with significant postantibiotic effect.77 Telithromycin is more active than erythromycin against Rickettsia, Bartonella and Coxiella burnettii, the causative agent of Q-fever. Telithromycin is ineffective against Ehrlichia chaffensis.71 Pharmacokinetics Approximately 90% of the oral dose is absorbed and 33% undergoes first pass metabolism mainly by the liver. Oral absorption is not affected by food intake.72 Peak plasma concentrations are achieved within 2.5 hours. Approximately 60-70% of telithromycin is protein bound. Telithromycin concentrates in white blood cells and respiratory tissues after absorption. At 8 hours after dosing, telithromycin concentrations in alveolar macrophages and epithelial fluid in the respiratory tract markedly exceed plasma concentrations.73 Telithromycin tonsillar tissue concentration exceeds the MIC 50 of group A beta-hemolytic streptococci. 74 Elimination of telithromycin is accomplished through metabolization by the liver 37% ; and excretion unchanged in feces 7% ; .75 Approximately 13% of telithromycin is excreted unchanged in the urine. About 50% of telithromycin metabolism occurs through the P450 system mainly by CYP3A4 enzyme. In patients with hepatic impairment, increased renal clearance may compensate for hepatic clearance.75, 76 Slight accumulation of telithromycin occurs 1.4 fold increase in Cmax and AUC ; in patients with mildsevere renal impairment. 75 Pharmacokinetic data in children are currently not available. Clinical studies and use In adults telithromycin has been shown to be as effective as macrolides and fluoroquinolones in treatment of community acquired pneumonia CAP ; including cases caused by penicillin- and erythromycin-resistant S. pneumoniae.77, 78 In preliminary studies, telithromycin has been shown to be effective in other respiratory tract infections such as chronic bronchitis, tonsillopharyngitis and acute maxillary sinusitis. Telithromycin at 800 mg day given for 7 to 10 days was as effecticve as macrolides and tenofovir.